ArticleOncology letters2016

Cost-effectiveness analysis of the bevacizumab-irinotecan regimen in the treatment of primary glioblastoma multiforme recurrences.

Daniel Ruiz-Sánchez et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.